National Bank of Canada FI Has $831,000 Holdings in Qiagen (NYSE:QGEN)

National Bank of Canada FI raised its stake in shares of Qiagen (NYSE:QGEN) by 17.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 19,055 shares of the company’s stock after purchasing an additional 2,819 shares during the period. National Bank of Canada FI’s holdings in Qiagen were worth $831,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in QGEN. Briaud Financial Planning Inc purchased a new position in shares of Qiagen during the third quarter valued at approximately $31,000. Toronto Dominion Bank bought a new position in Qiagen during the 3rd quarter valued at $41,000. Lindbrook Capital LLC boosted its holdings in Qiagen by 21.6% during the 4th quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock worth $58,000 after acquiring an additional 237 shares during the last quarter. Blue Trust Inc. boosted its holdings in Qiagen by 253.9% during the 4th quarter. Blue Trust Inc. now owns 3,974 shares of the company’s stock worth $161,000 after acquiring an additional 2,851 shares during the last quarter. Finally, Signaturefd LLC grew its stake in shares of Qiagen by 9.0% in the 3rd quarter. Signaturefd LLC now owns 4,686 shares of the company’s stock worth $190,000 after acquiring an additional 385 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Stock Performance

NYSE:QGEN opened at $45.77 on Thursday. The company has a market capitalization of $10.44 billion, a price-to-earnings ratio of 30.69, a PEG ratio of 3.75 and a beta of 0.42. The business has a 50 day moving average of $42.58 and a 200 day moving average of $43.06. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.45. Qiagen has a 1-year low of $34.74 and a 1-year high of $47.70.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Monday, April 29th. The company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The firm had revenue of $459.00 million for the quarter, compared to the consensus estimate of $453.91 million. During the same quarter in the previous year, the business earned $0.53 earnings per share. The company’s quarterly revenue was down 5.4% on a year-over-year basis. On average, sell-side analysts predict that Qiagen will post 2.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on QGEN shares. JPMorgan Chase & Co. upped their price objective on shares of Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a research report on Thursday, February 8th. Citigroup decreased their price target on Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a research report on Thursday, February 8th. Morgan Stanley upgraded Qiagen from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $49.48 to $51.00 in a report on Friday, February 16th. Finally, Stifel Nicolaus reduced their price objective on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research note on Wednesday, May 1st. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $50.95.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.